While G-CSF is commonly used after autologous HSCT and occasionally after allogeneic HSCT to minimize prolonged neutropenia and its associated morbidity and mortality [47,48,49], administration of G-CSF is not without risk [49,50]. The gene discussed is CSF3; the disease is Decreased total neutrophil count.